Shionogi & Co. reported that its pill-based Covid-19 treatment did not meet the primary endpoint in a global late-stage trial. The drug, known as Xocova, demonstrated a potent antiviral effect but failed to show a statistically significant reduction in 15 common symptoms of the illness. However, if approved, the drug was expected to generate $2 billion in annual sales. The company will collaborate with regulatory bodies to explore the possibility of making the drug available.
-
Uncategorized
A clinical trial conducted by neurosurgeons at Jaslok Hospital has shown that singing and dancing therapy can significantly improve the symptoms of Parkinson’s disease. Patients enrolled in the six-month study experienced positive changes in mood, balance, mobility, and cognition. Parkinson’s disease, a common neurodegenerative disorder, affects millions worldwide and impairs motor functions. Previous studies have also highlighted the benefits of music and dance interventions in improving symptoms and quality of life. Discover how singing and dancing have positively impacted the lives of Parkinson’s disease patients.
